AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28230639
Drug: mTOR inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor initiation in maintenance patients
Trial: 23578724
Drug: Mitomycin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin (12 mg/m² on day 1) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Trial: 23578724
Drug: Cisplatin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (60 mg/m² on days 1 and 29) with fluorouracil (1000 mg/m² per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Trial: 23578724
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (fluorouracil and cisplatin at weeks 11 and 14)
Trial: 17264222
Drug: HD+AA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD+AA (2 h of hemodialysis with amino acid infusion)
Trial: 17264222
Drug: HD-O (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-O (2 h of hemodialysis without amino acid infusion)
Trial: 11560566
Drug: Clozapine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (50 mg)
Trial: 9713556
Drug: Tibolone (TIB)
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (TIB) 2.5 mg/day (n = 28)
Trial: 9713556
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol 2 mg/day (PO) plus sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 26)
Trial: 9713556
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol patch (TTS) releasing 50 micrograms/day plus oral sequential dydrogesterone 10 mg/day for 14 of 28 days per cycle (n = 20)
Trial: 26016697
Drug: Digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital cognitive behavioural therapy (CBT) for insomnia (in addition to treatment as usual)
Trial: 28888927
Drug: Digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital cognitive behavioural therapy (CBT) for insomnia
Trial: 23032417
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (TIV), two doses 1 month apart
Trial: 20919540
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy based on routine hemodynamic parameters (blood pressure, heart rate, central venous pressure, daily fluid balance)
Trial: 17075113
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF)
Trial: 7732331
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg before breakfast)
Trial: 9005122
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg before bedtime)
Trial: 22491410
Drug: Patching therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patching therapy (1 hour per day per month of age until 8 months, then 50% of waking hours thereafter)
Trial: 19449344
Drug: Danshen dripping
RxNorm normalized name: DANSHEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danshen dripping pill (DDP)
Trial: 19449344
Drug: Non-DDP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-DDP treatment (Control)
Trial: 11208681
Drug: losartan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan (25 mg/d)
Trial: 3628831
Drug: Apomorphine HCl
RxNorm normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine HCl (0.25, 0.5, 0.75, 1.0 mg sc)
Trial: 3628831
Drug: Bromocriptine (2.5-3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5-3.75 mg/d po)
Trial: 1300301
Drug: 0.03% Flurbiprofen‐Na+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03% Flurbiprofen‐Na+ eye drops 1/2 hourly starting two hours before surgery
Trial: 6543134
Drug: Naftidrofuryl (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (100-200 mg/day for 7-14 days)
Trial: 31622058
Drug: Allokin-alpha therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allokin-alpha therapy (9 injections of s/c, 1.0 mg every other day)
Trial: 31622058
Drug: Valtrex (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valtrex (500 mg x 2 times/day, by mouth for two months)
Trial: 31168175
Drug: Allogeneic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic platelet gel
Trial: 24274958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (observed without treatment)
Trial: 23620599
Drug: Oxytocin inhalation
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin inhalation
Trial: 16238894
Drug: GAL-ER 24
RxNorm normalized name: Galfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAL-ER 24 mg qd (fasted)
Trial: 16238894
Drug: GAL-ER 24
RxNorm normalized name: Galfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAL-ER 24 mg qd (fed)
Trial: 16238894
Drug: GAL-IR 12
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAL-IR 12 mg bid (fasted)
Trial: 7769096
Drug: Vanadyl sulfate
RxNorm normalized name: Vanadyl Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanadyl sulfate (VS) 100 mg/d for 3 weeks
Trial: 2311809
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intramuscular bromocriptine retard
Trial: 2311809
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intramuscular bromocriptine retard
Trial: 2311809
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg intramuscular bromocriptine retard
Trial: 2311809
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intramuscular bromocriptine retard
Trial: 31795482
Drug: AAT-120 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAT-120 (60 or 120 mg/kg)
Trial: 31795482
Drug: AAT-60 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAT-60 (60 or 120 mg/kg)
Trial: 29779416
Drug: Indacaterol/Glycopyrronium (110/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/Glycopyrronium (110/50 μg once daily)
Trial: 29779416
Drug: Triple Therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Therapy (tiotropium [18 μg] once daily plus salmeterol/fluticasone propionate [50/500 μg] twice daily)
Trial: 26681262
Drug: Oxytocin treatment
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin treatment spray (placebo)
Trial: 26681262
Drug: Serotonin treatment
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin treatment spray (placebo)
Trial: 17234506
Drug: Formulation containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation containing 460 mg of omega-3 polyunsaturated fatty acids and/or 580 mg of soluble fibers
Trial: 16847182
Drug: Nasal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal treatment with amphotericin B for 8 weeks
Trial: 14676082
Drug: Etanercept, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept, 25 mg, subcutaneously twice a week for 24 weeks
Trial: 11030848
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion of 40 mg/kg
Trial: 8796393
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of i.v. nicardipine
Trial: 6722081
Drug: Nutrient-dense supplement
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient-dense supplement (A)
Trial: 29763373
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose challenge (OGC, 50 g glucose)
Trial: 27956074
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual, commenced immediately after discharge.
Trial: 27956074
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 15 weekly group sessions based on a CBT manual.
Trial: 25480457
Drug: Presentation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presentation of prognostic data as frequencies (e.g., 1 in 50)
Trial: 23782653
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care arm therapy.
Trial: 23782653
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care arm therapy
Trial: 18245179
Drug: olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine plus metformin (15 mg/day + 750 mg/day)
Trial: 18245179
Drug: olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine plus placebo (15 mg/day + placebo)
Trial: 18245179
Drug: olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: olanzapine plus metformin
Trial: 12682319
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean daily dose of 2.5 +/- 0.85)
Trial: 8969678
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of prostaglandin analogues to support gastric homeostasis
Trial: 1643676
Drug: Midazolam 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.75 mg.kg‐1
Trial: 1643676
Drug: Midazolam 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1.0 mg.kg‐1
Trial: 6442057
Drug: Auranofin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (oral gold salt)
Trial: 6442057
Drug: Sodium aurothiomalate
RxNorm normalized name: Sodium aurothiomalate
DrugBank: Sodium aurothiomalate (DB09276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium aurothiomalate (parenteral gold salt)
Trial: 6442057
Drug: Other baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other baseline antirheumatoids (D-penicillamine, antimalarials)
Trial: 31978611
Drug: Intravenous ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ribavirin for confirmed LF patients
Trial: 31978611
Drug: Standardized supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized supportive care and biological monitoring
Trial: 31171878
Drug: Triplet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet therapy (dabrafenib, trametinib, pembrolizumab)
Trial: 31171878
Drug: Doublet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet therapy (dabrafenib, trametinib, placebo)
Trial: 24628035
Drug: TA-8995 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-8995 (5, 10, 25, 50, 100, 150 mg single doses; 1, 2.5, 10, 25 mg once daily for 21-28 days)
Trial: 24628035
Drug: TA-8995 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-8995 (2.5 to 25 mg once daily)
Trial: 19200119
Drug: Treatment x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment x day interactions
Trial: 3533567
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg capsules of nifedipine
Trial: 3533567
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsules of nifedipine
Trial: 3533567
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg capsules of nifedipine
Trial: 3533567
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tablets of nifedipine
Trial: 3533567
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of nifedipine
Trial: 3533567
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg and 20 mg capsules and 20 mg tablets
Trial: 3533567
Drug: Nifedipine tablets
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine tablets
Trial: 31778632
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg IV)
Trial: 31778632
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg IV)
Trial: 28420629
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg intravenous at induction of anaesthesia)
Trial: 25606834
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (5 mV, 650 nm, 20 minutes a day, 5 days a week for 4 weeks)
Trial: 25606834
Drug: Inactive dummy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive dummy treatment (placebo)
Trial: 24307207
Drug: zuclopenthixol at
RxNorm normalized name: zuclopenthixol
DrugBank: Zuclopenthixol (DB01624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zuclopenthixol at a dose of 2-20 mg/d
Trial: 11598604
Drug: hGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH treatment (28 IU/m2/wk)
Trial: 7575274
Drug: Decapinol mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decapinol mouthwash 2 mg/mL
Trial: 2105988
Drug: Prostacyclin (PGI2)
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (PGI2) administration
Trial: 6157203
Drug: Econazole nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole nitrate 150 mg per day for 3 days
Trial: 6157203
Drug: Econazole nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole nitrate 50 mg per day for 14 days
Trial: 23955709
Drug: 25,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25,000 IU retinyl palmitate capsule daily for 6 months
Trial: 23955709
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule daily for 6 months
Trial: 19216763
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (MT) consisting of mobilisations, exercise therapy for the cervical and thoracic spine, and postural correction.
Trial: 17646620
Drug: Rivastigmine patches
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patches
Trial: 9000318
Drug: Neuroleptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic treatment (traditional antipsychotic drugs)
Trial: 1361435
Drug: Alfuzosin (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (alpha 1-receptor-blocking compound)
Trial: 6437263
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg D2343
Trial: 6437263
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terbutaline
Trial: 20237029
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (100 mg every 4 h for 6 days)
Trial: 19000845
Drug: Computerized educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized educational session and provision of 200 folate tablets
Trial: 1423181
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg)
Trial: 14634409
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (50 mg, adjustable to 100 or 25 mg)
Trial: 10995004
Drug: 9-cis retinoic
RxNorm normalized name: 9-cis-retinoic acid
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-cis retinoic acid (9CRA) at 60 mg/m2 daily for 1 week, then escalating to 100 mg/m2 during the second week, up to a maximum of 140 mg/m2 for a planned duration of 48 weeks.
Trial: 1469177
Drug: Selective Decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Decontamination of the Digestive Tract (SDD) with Cefotaxime i.v. (6 g/day) for the first four days and Polymyxin E, Tobramycin and Amphotericin B at the oropharyngeal and gastrointestinal level throughout the whole stay
Trial: 30101278
Drug: Morphine (Control)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (Control)
Trial: 29540661
Drug: N-acetylcysteine 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 900 mg/day for 7 days before surgery
Trial: 26963952
Drug: Older men
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Older men with age-related low T levels (4% positive for antipituitary antibodies)
Trial: 26963952
Drug: Healthy young
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy young and older eugonadal men (0% positive for antipituitary antibodies)
Trial: 24687829
Drug: Bevacizumab-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-containing therapy (BEV-CT)
Trial: 22574084
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with free iron tablets (A group)
Trial: 16200253
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (5 g/day for 28 days)
Trial: 1290634
Drug: Disodium pamidronate
RxNorm normalized name: Disodium pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium pamidronate (APD) administered as a single i.v. infusion of 30, 60 or 90 mg depending on serum calcium.
Trial: 1290634
Drug: Mithramycin given
RxNorm normalized name: Mithramycine
DrugBank: Plicamycin (DB06810)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mithramycin given in doses of 1.25 mg, repeated if necessary within the first three days.
Trial: 3937509
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg tablets, 1 tablet twice daily)
Trial: 3937509
Drug: Indapamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5 mg tablets, 1 tablet every morning)
Trial: 30785667
Drug: Laxative bowel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative bowel preparation (LBP)
Trial: 30045006
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg in the morning and 5 mg at bedtime for 12 months)
Trial: 30045006
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 x 1 tablet for 12 months)
Trial: 22585767
Drug: suma/nap 10/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suma/nap 10/60 mg
Trial: 22585767
Drug: suma/nap 30/180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suma/nap 30/180 mg
Trial: 22585767
Drug: suma/nap 85/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suma/nap 85/500 mg
Trial: 19892351
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat diet plus 40 mg/day of pravastatin
Trial: 10512282
Drug: Ropivacaine (286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (286 mg, 66 mL)
Trial: 10512282
Drug: Saline (66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (66 mL)
Trial: 2177648
Drug: Dydrogesterone 20
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 20 mg/day for 12 days each calendar month for 3 months, then 10 mg/day for a further 3 months
Trial: 2177648
Drug: Dydrogesterone 10
RxNorm normalized name: dydrogesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg/day in reverse sequence
Trial: 2177648
Drug: Both dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both dydrogesterone doses